A5046863866- Pharmacological Effects and Toxicity Studies
- Melanoma and MAPK Pathways
- Adrenal Hormones and Disorders
- Adrenal and Paraganglionic Tumors
- Pharmaceutical Practices and Patient Outcomes
- Renal cell carcinoma treatment
- Glioma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Sarcoma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Renal Transplantation Outcomes and Treatments
- Colorectal Cancer Treatments and Studies
- Quinazolinone synthesis and applications
- Vascular Tumors and Angiosarcomas
- Pituitary Gland Disorders and Treatments
- Cancer therapeutics and mechanisms
- Safe Handling of Antineoplastic Drugs
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- PARP inhibition in cancer therapy
- HIV/AIDS drug development and treatment
- Computational Drug Discovery Methods
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
Hôpital Cochin
2020-2024
Assistance Publique – Hôpitaux de Paris
2020-2024
Inserm
2020-2023
Centre National de la Recherche Scientifique
2020-2023
Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale
2023
Université Paris Cité
2020-2023
Sorbonne Paris Cité
2020-2023
Délégation Paris 5
2022
Descartes (Belgium)
2022
Hôpital Broca
2021
High interindividual variability (IIV) of the clinical response to epidermal growth factor receptor (EGFR) inhibitors such as osimertinib in non-small-cell lung cancer (NSCLC) might be related IIV plasma exposure. The aim this study was evaluate exposure−response relationship for toxicity and efficacy unselected patients with advanced EGFR-mutant NSCLC. This retrospective analysis included 87 treated osimertinib. Exposure−toxicity performed entire cohort survival only second-line (n = 45)....
Tacrolimus (TAC) is the cornerstone of immunosuppressive therapy in liver transplantation. This study aimed at elucidating interplay between pharmacogenetic determinants TAC whole blood and intracellular exposures as well pharmacokinetic-pharmacodynamic relationship both compartments. Complete pharmacokinetic profiles (Predose, 20 min, 40 1h, 2h, 3h, 4h, 6h, 8h, 12h post drug intake) twice daily peripheral mononuclear cells (PBMC) were collected 32 transplanted patients first ten days A...
Patients treated with dabrafenib/trametinib (DAB/TRA) exhibit a large interindividual variability in clinical outcomes. The aims of this study were to characterize the pharmacokinetics DAB, hydroxy-dabrafenib (OHD), and TRA BRAF-mutated patients investigate exposure–response relationship for toxicity efficacy metastatic melanoma (MM) patients. Univariate Fisher Wilcoxon models including drug systemic exposure (area under plasma concentration curve, AUC) used identify prognostic factors onset...
Factors associated with olaparib toxicity remain unknown in ovarian cancer patients. The large inter-individual variability pharmacokinetics could contribute to the onset of early significant adverse events (SAE). We aimed retrospectively analyze pharmacokinetic/pharmacodynamic relationship for patients from “real life” data. clinical endpoint was SAE (grade III/IV or dose reduction/discontinuation). Plasma concentration assayed using liquid chromatography at any time over dosing interval....
Lipin-1 deficiency is a life-threatening disease that causes severe rhabdomyolysis (RM) and chronic symptoms associated with oxidative stress. In the absence of treatment, Hydroxychloroquine sulfate (HCQ) was administered to patients off label use on compassionate basis in order improve their physical conditions.Eleven LPIN1 mutations were treated HCQ. Clinical biological efficacy tolerance assessed, including pain quality life, capacities, cardiopulmonary parameters, creatine kinase levels...
Background: BRAF and MEK inhibitors are cornerstones of the redifferentiation strategy in metastatic radioactive iodine (RAI)-resistant mutant thyroid cancers. We explored exposure–toxicity relationship for dose-limiting toxicity (DLT) onset patients treated with dabrafenib and/or trametinib investigated whether plasma exposure was associated RAI reuptake. Methods: conducted a retrospective monocentric study which we reviewed electronic medical records our institution tumor strategy, whom...
Background: Pazopanib (PAZ) is an oral angiogenesis inhibitor approved to treat soft tissue sarcoma (STS) but associated with a large interpatient pharmacokinetic (PK) variability and narrow therapeutic index. We aimed define the specific threshold of PAZ trough concentration (Cmin) better progression-free survival (PFS) in STS patients. Methods: In this observational study, Cmin was monitored over treatment course. For primary endpoint, 3-month PFS analyzed logistic regression. Second, we...
Patients treated with dabrafenib and trametinib for BRAF
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Background. Pazopanib is an oral angiogenesis inhibitor approved to treat soft tissue sarcoma (STS) but associated with large interpatient pharmacokinetic (PK) variability and narrow therapeutic index. In order improve its clinical use, this study aimed define specific threshold of pazopanib trough concentration (Cmin) better progression free survival in STS patients. Methods. observational study, Cmin was monitored over the treatment course. For primary endpoint, 3-month PFS analyzed...
Abstract Background : The risk of drug interactions (DDI) has become a major issue in cancer patient care. However, data sarcoma patients are scarce. We aimed to evaluate the frequency DDI with antitumor treatments, identify factors for and impact pharmacist evaluation before anticancer treatment. Patients Methods performed retrospective review consecutive starting chemotherapy (CT) or Tyrosine kinase inhibitor (TKI). A medication reconciliation established an early toxicity assessment....
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Intrauterine exposure to baclofen can lead syndrome of withdrawal during the first days newborn. We report case a full-term baby exposed pregnancy. The mother was treated with 10 mg 4 times daily. Blood samples were collected from before entering labor and at H0, H11, H31, H102 after birth measure concentrations monitor its elimination. Baclofen maternal neonate pharmacokinetics (PK) placental transfer assessed using physiologically based PK model. in followed monoexponential elimination...